Review

Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Current Trends and Controversies

Stephanie K. Schaub, MD, Pehr E. Hartvigson, MD, Michael I. Lock, MD, CCFP, FRCPC, FCFP, Morten Høyer, MD, PhD, Thomas B. Brunner, MD, Higinia R. Cardenes, MD, PhD, Laura A. Dawson, MD, FRCPC, FASTRO, Edward Y. Kim, MD, Nina A. Mayr, MD, FASTRO, FAAA, Simon S. Lo, MB, ChB, FACP, FASTRO, and Smith Apisarnthanarax, MD

Abstract

Hepatocellular carcinoma is the fourth leading cause of cancer-related death worldwide. Depending on the extent of disease and competing comorbidities for mortality, multiple liver-directed therapy options exist for the treatment of hepatocellular carcinoma. Advancements in radiation oncology have led to the emergence of stereotactic body radiation therapy as a promising liver-directed therapy, which delivers high doses of radiation with a steep dose gradient to maximize local tumor control and minimize radiation-induced treatment toxicity. In this study, we review the current clinical data as well as the unresolved issues and controversies regarding stereotactic body radiation therapy for hepatocellular carcinoma: (1) Is there a radiation dose–response relationship with hepatocellular carcinoma? (2) What are the optimal dosimetric predictors of radiation-induced liver disease, and do they differ for patients with varying liver function? (3) How do we assess treatment response on imaging? (4) How does stereotactic body radiation therapy compare to other liver-directed therapy modalities, including proton beam therapy? Based on the current literature discussed, this review highlights future possible research and clinical directions.

Keywords

HCC, hepatocellular carcinoma, SBRT, stereotactic body radiation therapy, SABR, stereotactic ablative radiation therapy, proton therapy

Abbreviations

BCLC, Barcelona Conference; BED, biologically equivalent dose; CP, Child-Turcotte-Pugh; CR, complete responder; cRILD, classical radiation-induced liver disease; EASL, European Association for the Study of Liver Diseases; EQD2, equivalent dose if given in 2 Gy fractions; HCC, hepatocellular carcinoma; LC, local control; LDT, liver-directed therapy; LI-RADS, Liver Imaging Reporting and Data System; LRCP, London Regional Cancer Program; mRECIST, modified Response Evaluation Criteria in Solid Tumors; MTD, maximally tolerated dose; MVA, multivariate analysis; NCDB, National Cancer Database; ncRILD, nonclassical radiation-induced liver disease; OLT, orthotopic liver transplantation; OS, overall survival; PBS, pencil beam scanning; PBT, proton therapy

Corresponding Author:
Simon S. Lo, MB, ChB, FACP, FASTRO, Department of Radiation Oncology, University of Washington, 1959 NE Pacific Street, Seattle, WA, USA.
Email: simonslo@uw.edu

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Introduction

Hepatocellular carcinoma (HCC) is the third most common gastrointestinal malignancy and the sixth deadliest solid malignancy with increasing incidence in the United States. Worldwide, HCC is the fourth leading cause of cancer-related death. The majority of patients with HCC have underlying chronic liver disease caused by viral hepatitis and/or nonalcoholic/ alcoholic fatty liver disease. For many patients, their chronic liver disease presents a competing comorbidity risk for mortality.

Surgery remains the gold standard for curative treatment and includes either a partial hepatectomy or liver transplantation. Transplantation is associated with an 84% 2-year overall survival (OS)%; however, only 15% to 30% are candidates due to tumor extent and underlying liver dysfunction. For these patients, other liver-directed therapies (LDTs) are evaluated in a multidisciplinary setting with various treatment intents, such as bridge-to-transplant, definitive/curative treatment, and/or palliation. Most patients with nonmetastatic HCC receive one or more of the following LDT over the course of their treatment: radiofrequency ablation (RFA), transarterial chemoembolization (TACE), transarterial radioembolization (TARE), and external beam radiotherapy (RT). Until recently, RT was used cautiously due to the narrow therapeutic window when balancing tumor control against radiation-induced liver disease (RILD).5

However, technological advancements in radiation oncology over the past 10 to 15 years have enabled the development of stereotactic body RT (SBRT), which delivers highly conformal dose distributions with a rapid dose drop off that offers the ability to spare large portions of the liver while simultaneously allowing for dose escalation with ablative potential within the tumor. Stereotactic body RT presents an alternative and/or combined modality to use with other LDTs. In 2000, the Barcelona Conference (BCLC) outlined the optimal treatment algorithms for primary liver cancer without inclusion of RT, because it was only until afterward that RT emerged as a promising treatment for HCC.4 However, SBRT is now included in the most recent version of the National Comprehensive Cancer Network guidelines for primary liver cancer under the indication for unresectable disease or medically inoperable patients.6

Despite the mounting worldwide evidence of SBRT as an acceptable LDT option for patients with HCC, several important issues remain unresolved. In addition to reviewing the current clinical SBRT data, we review unresolved issues and controversies regarding the use of SBRT for HCC, specifically:

1. Is there a radiation dose–response relationship with HCC?
2. Dosimetric predictors of hepatotoxicity: do Child-Pugh B patients have differing constraints?
3. How do we assess treatment response on imaging?
4. How does SBRT compare to other LDT modalities, including proton beam therapy (PBT)?

Overview of Clinical SBRT Data

Prospective clinical trials of liver SBRT have demonstrated high rates of local control (LC), typically defined as no progression of disease per RECIST criteria, ranging from 87% to 100% at 1 to 3 years (Table 1).7-9 Local control may decrease slightly to 82% for patients with worse baseline liver function such as Child-Turcotte-Pugh (CP)-B patients, which may be related to lower tumor dose delivered in order to decrease the risk of RILD.7,9,13 Evidence for the safety and efficacy of SBRT for HCC is the strongest in patients with well-compensated baseline cirrhosis (eg, CP-A). In 2006, Mendez-Romero et al reported the first prospective evidence for liver SBRT demonstrating promising LC and safety in 8 patients with HCC with 11 total lesions and 34 patients with liver metastases; however, 1 CP-B patient experienced RILD-related death.12 Kang et al followed with a prospective phase II trial in 47 patients with HCC (87% CP-A, 13% CP-B) with 56 lesions showing excellent 2-year LC of 95% after SBRT with a median total dose of 57 Gy (range: 42-60) in 3 fractions.11 Grade ≥3 toxicity was notable for 4.3% grade 4 GI ulcer perforation, 6.4% grade 3 GI toxicity, 8.5% ascites formation, 10.6% grade 3 thrombocytopenia, and 4.3% grade 4 hyperbilirubinemia. Princess Margaret Cancer Centre in Toronto reported the largest analysis in 2013 with 102 patients with HCC (CP-A 100%) treated in a consecutive phase I to II study of 6-fraction SBRT to a median total dose of 36 Gy (range: 24-54 Gy) showing excellent 1-year LC of 87% when treating lesions with a median diameter of 7.2 cm (range: 1.4-23.1 cm). This trial reported hepatotoxicity in 30% of patients. Seven patient deaths (7%) were possibly related to RILD. This increased rate of RILD-related death could be related to the large tumor volumes treated and the high number of patients (55%) with portal vein tumor thrombosis (PVTT), which is a known independent poor prognostic factor.

Culleton et al at Princess Margaret later published a prospective study on 29 patients with HCC having CP-B7 + baseline cirrhosis (69% B7) and 76% PVTT which found LC of 65% at 1 year (somewhat lower than historical studies) and a
| Study, Year, Type of Data | Median f/u, months | n | Lesion # | CP-B % | PVTT | Prior LDT | Median GTV Diameter (Range), cm | Median Dose Gy/ fx, (Range) | LC | OS | G ≥ 3 Toxicity, % |
|--------------------------|--------------------|---|----------|--------|-------|----------|---------------------------------|-----------------------------|----|----|------------------|
| Mendez-Romero, 2006, phase I/II<sup>12</sup> | 13 | 8 | 11 | 25% | 25% | NR | 3.5 (0.5-7.2) | <4 cm, no cirrhosis: 37.5/3 ≥4 cm and cirrhosis: 25/5 or 30/3 | 75% | 75% | 13% |
| Kang, 2012, phase II<sup>11</sup> | 17 | 47 | 56 | 13% | 11% | 2.9 (1.3-7.8) | 57/3 (42-60) | 2 years, 95% | 2 years, 95% | – 4% GI ulcer perforation – 6% G3 GI toxicity – 9% ascites – 11% G3 thrombocytopenia – 4% G3 hyperbilirubinemia | 30% |
| Bujold, 2013, phase I/II<sup>7</sup> | 31 | 102 | Multiple in 61% | 0% | 55% | 52% | 7.2 (1.4-23.1) | 36/6 (24-54) | 87% | 87% | – 4% GI ulcer perforation – 6% G3 GI toxicity – 9% ascites – 11% G3 thrombocytopenia – 4% G3 hyperbilirubinemia | 30% |
| Culleton, 2014, phase I/II<sup>10</sup> | NR | 29 | Median 2 lesions | 97% (69% B7) | 76% | 14% | Sum of all lesions: 8.6 (4.1-23.6) | 30/6 (19.7-46.8) | 65% | 32.3% | 63% had decline in CP score by ≥2 at 3 months | – 4% GI ulcer perforation – 6% G3 GI toxicity – 9% ascites – 11% G3 thrombocytopenia – 4% G3 hyperbilirubinemia | 30% |
| Lasley, 2015, phase I/II<sup>9</sup> | CP-A: 33 | 59 | 65 | 36% B7/8+: 20% | 15% | Volume: 33.6 cc | CP-A: 48/5 (36-48) | CP-A: 91% | CP-A: 94% | CP-A: 11% | CP-A: 38% |
| | CP-B: 46 | | | | | (2-107) | CP-B: 40/5 | CP-B: 82% | CP-B: 57% | CP-B: 38% | | |

Abbreviations: CP, Child-Pugh; f/u, follow-up; n, number of patients; fx, fraction; G, grade; GI, gastrointestinal; GTV, gross tumor volume; HCC, hepatocellular carcinoma; LC, local control; LDT, liver-directed therapy; NR, not reported; OS, overall survival; PVTT, portal vein tumor thrombosis; SBRT, stereotactic body radiation therapy.

<sup>a</sup>At 1 year unless otherwise stated.
median OS of 8 months.\textsuperscript{10} Patients had locally advanced HCC that was estimated to be the primary life-threatening health problem (eg, PVTT). This trial showed that CP $\geq$ B8 and alpha fetoprotein (AFP) $> 4491$ ng/mL were poor prognostic factors. The significance of advanced CP-score was further demonstrated by CP-B7 patients having a significantly higher median OS of 9.9 months versus 2.8 months in CP-B8+ patients ($P = .011$), suggesting that patients with CP-B8+ should not be treated with SBRT off of trials designed to reduce risk and improve outcomes. Elevated rates of hepatotoxicity were observed in this trial, as measured by CP-score increase of 2 or greater (CP + 2) of 63\% at 3 months.

Cardenes and colleagues at Indiana University analyzed the results of a phase I/II trial of SBRT for HCC restricted to CP-A (n = 38) and CP-B7 patients (n = 21) with lesions treated to a median total dose of 48 Gy in 3 fractions (range: 36-48) and 40 Gy in 5 fractions, respectively.\textsuperscript{9} One-year LC remained excellent at 91\% in CP-A patients with a modest decrease to 82\% in CP-B7 patients. Consistent with the results from Princess Margaret demonstrating increased toxicity in CP-B patients, Indiana University reported rates of grade 3+ liver toxicity of 11\% versus 38\% in CP-A and -B patients, respectively. Similarly, Scorsetti \textit{et al} in Milan reported a prospective observational trial of 43 patients with HCC (47\% CP-B) with 63 lesions showing LC of 86\% and 64\% at 1 and 2 years, respectively, with no incidence of grade 3+ hepatotoxicity using a tumor size-based dose/fraction scheme.\textsuperscript{13} One-year OS ranged between 32\% and 94\% in the prospective trials described earlier. The lowest survival rates were reported in the study on CP-B patients (especially CP-B8+),\textsuperscript{10} whereas the best results were reported in CP-A patients.\textsuperscript{9}

Besides demonstrating the prognostic significance of the CP score, these studies showed that PVTT, multinodular disease, and high serum AFP portend poor prognosis. Since these are often considered relative or absolute contraindications for other non-SBRT LDT, this makes direct comparisons between SBRT and other LDT challenging. Additionally, many patients undergoing SBRT were previously treated with other LDTs (range: 44-100\%), which may confound local control, intrahepatic control, and hepatotoxicity reporting.\textsuperscript{3,11,13}

The presence of PVTT, which often prohibits the feasibility of other LDTs, has been analyzed specifically in the context of SBRT.\textsuperscript{14-16} Kang \textit{et al} performed a comparison of 101 patients with HCC (CP-A 87\%) treated with either SBRT followed by TACE, TACE followed by SBRT, or SBRT alone and demonstrated no significant differences in LC with intrahepatic response rates ranging from 83\% to 88\%. Local control for patients with PVTT (range: 67-74\%) also did not differ between the 3 groups.\textsuperscript{15} Combined modality therapy of SBRT and TACE over SBRT alone trended toward improved control. Moreover, Xi \textit{et al} showed in 41 patients with HCC having PVTT or inferior vena cava tumor thrombosis that portal vein \textit{branch} thrombosis was associated with significantly longer survival compared to portal vein \textit{trunk} thrombosis or inferior vena cava thrombosis.\textsuperscript{14} In this study, the only independent predictive factor associated with improved survival was response to RT. Furthermore, a propensity score analysis in patients with PVTT showed significant survival benefit of 10.9 months versus 4.1 months ($P < .001$) with combined therapy of TACE and SBRT (n = 112) compared to TACE alone (n = 735).\textsuperscript{16}

Recently, Yoon \textit{et al} published the results of the START trial, which randomized 90 CP-A patients with liver-confined HCC and macrovascular invasion to either sorafenib or TACE followed by moderately hypofractionated RT (TACE-RT, median 40 Gy [range: 30-45 Gy] in either 2.5 or 3 Gy fractions).\textsuperscript{17} They found significant improvements with the combination of TACE-RT versus sorafenib in 12-week progression-free survival (87\% vs 34\%), 24-week radiographic response rate (33\% vs 2\%), median time to progression (31 vs 12 weeks), and OS (55 vs 43 months). These findings suggest SBRT and hypofractionated RT may pair well with other LDTs in managing patients with PVTT and other forms of macrovascular invasion.

A limitation of SBRT for HCC is the lack of long-term prospective data beyond 2 years. At a median follow-up of 28.7 months, Kwon \textit{et al} retrospectively demonstrated 3-year local control of 67.8\% and OS of 58.6\% in 42 small patients with HCC (9.5\% CP-B), deemed ineligible for other LDTs, treated to a median dose of 33 Gy (range: 30-39) in 3 consecutive days.\textsuperscript{18} In a similar patient cohort of 132 small HCC (14\% CP-B) treated with SBRT to 42 to 46 Gy in 3 to 5 consecutive days, Su \textit{et al} showed a 5-year progression-free survival and OS of 36.4\% and 64.3\%, respectively; however, long-term LC data beyond 1-year was not reported.\textsuperscript{19}

\textbf{Radiation Dose Response and the Role of Dose Escalation}

In the era of rapid technological advancement, the technical ability to escalate dose may be outstripping our knowledge of whether dose escalation is beneficial in SBRT for HCC. Our understanding of the nature of the dose response for HCC is based on tumor control probability (TCP) models, expert opinion, and heterogeneous clinical case series reports. Understanding the dose response curve, if one exists, provides clinicians the ability to appropriately escalate dose to provide a defined amount of incremental tumor control. This escalation often comes at the price of increased risk of toxicity, which in the case of hepatic irradiation can be fatal.\textsuperscript{20} For example, if the dose response is sigmoidal, small changes in dose in the middle dose range of the curve may result in large increases in TCP. However, if the dose increase is entertained at the upper or lower flatter portions of the curve, large dose escalations may provide minimal improvement in TCP at the price of an increasing risk of hepatotoxicity.

\textbf{Dose response models and literature review}. As the optimal dose is unknown and varied dose data are relatively limited in this heterogeneous patient group, models were developed to clarify whether a dose–response relationship exists for HCC. Lausch \textit{et al} at the London Regional Cancer Program (LRCP) in
Ontario, Canada, used data from a single institution case series to develop the first logistic TCP model to fit observed HCC data. They retrospectively reviewed 36 patients with HCC treated with median 4 Gy per fraction (range: 2-10 Gy) to a median cumulative dose of 52 Gy (range: 29-83 Gy) on a radio-biologically guided dose escalation protocol. The protocol called for prescribing the highest possible dose that met the constraint of keeping the estimated risk of RILD to \( \leq 5\% \). They demonstrated that the D50 (dose that would result in a 50% LC) at 6 months was 53 Gy equivalent dose if given in 2 Gy fractions (EQD2). In contrast, the D50 for metastatic disease to the liver was 70 Gy EQD2 demonstrating that HCC is relatively radioresistant compared to other tumor types, including colorectal carcinoma metastatic to the liver. The D90 was found to be 84 Gy EQD2 suggesting that increasing dose results in increased LC. Jang et al developed a logistic TCP model based on tumor size. This Korean group was able to demonstrate that higher doses (cumulative and per fraction) are required to achieve the same TCP for larger lesions. For example, for lesions \( \leq 5 \) cm vs lesions > 5 cm, doses had to be escalated from 51 to 61 Gy in 3 fractions to achieve a 2-year LC of 90%. Of note, only 17% of patients had lesions > 5 cm and the median size of the lesion was 3 cm. The Korean TCP model also indicated that the D50 was 62.9 Gy EQD2 (range: 58-69 Gy EQD2) which was higher than that shown by LRPCP of D50 = 53 Gy EQD2 (SD 48-59 Gy EQD2), which may be likely due to the longer time period selected (2 years vs 6 months).

In contrast to these models, recently published TCP model developed with multi-institutional data for 394 patients with HCC by Ohri et al concluded that there does not appear to be a significant dose response for early stage HCC tumors. Of note, this group did find a dose response for patients with liver metastases, where a biologically equivalent dose (BED) over 100 Gy10 had an LC of 93% at 2 years compared to 70% for those treated with \( \leq 100 \) Gy10. Data was extracted from 5 HCC eligible trials that reported outcomes by dose representing one of the largest data sets used for modeling. Actuarial LC curves were generated from this consolidated data set, and outcomes were compared to the BED calculated by the linear quadratic equation. Within the reported range of 33 to 60 Gy in 3 to 5 fractions (BED 60-180 Gy10), the LC rate at 2 years was 89% for patients treated with \( \leq 100 \) Gy10 and >100 Gy10 (\( P = .972 \)). The authors highlight that half the data set was treated within a relatively conservative 60 to 72 Gy10 BED range and achieved a 90% LC rate at 2 years. Based on this model, Ohri et al recommended that conservative schedules, such as 8 to 10 Gy per fraction in 5 fractions, be used and that doses > 50 Gy in 5 fractions should not be used due to the increased risk of toxicity.

Most current models that guide our dose selection are derived from single institutions and small data sets. Does the broader literature confirm the conclusions? The earliest data suggesting a dose response comes from hepatic irradiation case series trials, where a wide range of doses were used within a dose escalation maximally tolerated dose (MTD) protocol or in radiobiologically guided studies.

We performed a systematic literature review of trials with LC data at 2 years, with limited dose ranges to allow for an appropriate link with outcome and of sufficient size to avoid individual patients from skewing the data (defined as \( >50 \) patients). The trials in this review included terms “hepatocellular and radiation” and “liver and SBRT” in a PubMed search performed on January 19, 2018. Equivalent dose if given in 2 Gy fractions and BED, assuming an \( \alpha/\beta \) ratio of 10, were calculated for all trials to qualitatively identify any dose response. Based on this review, these models fit well with a review of the literature, where an ordering of published data by local control relative to dose suggests that 2-year LC rates of 90% can be achieved with common dose regimens such as 40 to 48 Gy in 3 fractions and 35 to 40 Gy in 5 fractions (Table 2). Given the importance of CP score, many institutions recommend higher fractionation schemes for CP-B7+ patients. The EQD2 range for these regimens is between 50 Gy and 78 Gy. One important caveat to this comparison and the Ohri TCP model is that this method of trial selection results in a collection of trials with an arguably narrow range of doses and apply only to relatively small lesions. Trials with a wider range of doses and tumor sizes, such as the trial by the Princess Margaret, have more varied outcomes that differ from the majority of included trials.

**Dose escalation and LC in the context of survival and toxicity.** Even if a significant dose–response relationship existed for LC, another critical issue to consider is whether LC with SBRT is associated with improved OS. In a 2013 prospective report on 102 patients with HCC (CP-A 100%) series by Princess Margaret, Bujold et al demonstrated that patients receiving <30 Gy in 6 fractions (BED = 45 Gy10, EQD2 = 38 Gy) versus \( \geq 30 \) Gy had a 2-year LC rate of 66% vs 85%. This difference did not translate into an improvement in OS, with the authors stating that out-of-field liver recurrences were a prominent cause of progression in their case series. However, there are data that there is a critical dose threshold for local control and that escalating beyond this threshold does translate into an OS advantage. In one of the largest reports in the literature, a Korean group treated 108 patients with HCC (CP-A 90%) with a formal dose escalation protocol starting from 33 Gy in 3 fractions to 60 Gy in 3 fractions. The median dose was 51 Gy in 3 fractions (BED 138 Gy10, EQD2 = 115 Gy). This group demonstrated that the 2-year LC rate was 100% at doses greater than 54 Gy in 3 fractions (BED = 152 Gy10, EQD2 = 126 Gy). In addition, patients achieving this dose had a 71% OS at 2 years. Conversely, if patients received <45 Gy in 3 fractions (BED = 113 Gy10, EQD2 = 94 Gy), the 2-year LC and OS rate dropped to 64% and 30%, respectively. Another large trial from South Korea studied 398 patients (CP-A 73.9%) from 10 different centers. Based on multivariable analysis, this multicenter trial demonstrated an OS benefit for patients receiving BED \( \geq 53 \) Gy10.

In a similar trial in North American patients, the Indiana University group also used 3 fractions in a formal dose escalation protocol. Starting at 36 Gy in 3 fractions, this group...
increased dose in 2 Gy per fraction steps and found that 48 Gy in 3 fractions (BED = 125 Gy$_{10}$, EQD2 = 104 Gy) resulted in excellent results (2-year LC rate of 90%) and minimal toxicity in CP-A patients. Compared to the Korean data by Jang et al., an interesting conclusion is that increasing the EQD2 even from 104 Gy to 126 Gy results in an increase in LC from 90% to 100%.22 The clinical importance of this possible ablative improvement would have to be weighed against the possible increased toxicity risk in individual patients, especially in patients with higher CP scores given that an EQD2 of 104 Gy already achieves a very high durable LC rate.

Patients with HCC often have underlying cirrhosis or have tumors located near important organs at risk such as gastroduodenal or hepatobiliary structures. This may limit the ability to dose escalate in a large portion of patients. The CP-B patients and/or those with low platelets have less dose–volume dependency and may be harmed by increasing radiation dose. Data from Indiana University, among others, have demonstrated an increased risk of toxicity for patients with hepatic insufficiency as measured by the CP score.8 The Indiana University group went further and was able to determine an MTD of 40 Gy in 5 fractions (BED = 72 Gy$_{10}$, EQD2 = 60 Gy) for CP-B patients, and a CP score greater than B7 was associated with an increased risk of RILD. Therefore, the question of dose response beyond 60 Gy EQD2 in this situation may be moot, as no further dose escalations are possible in this higher risk population. Given that patients in CP-A group were able to tolerate up to 48 Gy in 3 fractions (BED = 124 Gy$_{10}$, EQD2 = 104 Gy) and achieve good results, should techniques such as PBT be considered to provide more normal liver sparing and a higher chance of dose escalation in patients with hepatic insufficiency? Perhaps, this may not be a useful strategy, as regression data from LRCP suggested that CP-B patients do not benefit from dose escalation.34 In contrast, in that same study of 195 patients, dose escalation was found to provide a significant improvement in OS for CP-A patients.

**Limitations and caveats.** There are limitations to this investigation of whether a dose response or at least a threshold dose exists for HCC. As noted in Table 2 and in other reviews,35 the published literature may have a range of doses that might reflect a narrow portion of the dose–response curve. Despite the ability to achieve higher doses of significantly over 100 Gy EQD2 in certain patients, clinicians are rightly reluctant to give these doses routinely. Therefore, there are fewer high dose data points, which limit the ability to model the dose–response curve.21,22 Furthermore, outcomes may be driven by factors other than dose alone. Nomograms and multivariable models demonstrate that liver function and tumor size are much more significant in determining survival compared to an increase in radiation dose. This is consistent with the Japanese data from Yamashita who retrospectively studied 79 patients with HCC from 7 Japanese institutions.24 They found no difference in LC with doses above or below 100 Gy$_{10}$. Their 2-year LC rate was 75% with a median BED of 106 Gy$_{10}$. However, there was a statistically important difference in outcome when comparing lesions above and below 3 cm in maximum diameter (LC 64% vs 85%). Size is a predominant factor in outcome. The dose response noted above may simply reflect the size variation in trials and the ability to give a higher dose to smaller lesions (Table 2).

The clinical benefit of radiation, particularly OS, may be driven less by the tumor–dose control interaction and more by the underlying fitness of the patient and hepatic insufficiency,

---

Table 2. Summary of HCC Radiotherapy Studies in Order of Local Control at 2 Years.*

| Study, Year | n | CP-B % | Median Tumor Diameter, cm | Dose (Range) /fx | BED Gy$_{10}$ | EQD2 | Dose-Prescription Point | 1-Year OS | 2-Year LC |
|-------------|---|--------|--------------------------|-----------------|-------------|------|------------------------|----------|----------|
| Yamashita, 2015$^{24}$ | 79 | 11%    | 2.7                      | 48 Gy/4-10      | 71-106      | 59-88 | D95% PTV               | 78%      | 64%      |
| Bujold, 2013$^7$ | 102 | 0%      | 9.9                      | 24-54 Gy/6      | 34-103      | 28-86 | D95% PTV modified based on effective liver volume irradiated | 75%      | 74%      |
| Bibault, 2013$^{25}$ | 75  | 11%    | 3.7                      | 40-45 Gy/3      | 72-85       | 60-71 | 80% IDL D95% PTV       | 79%      | 90%      |
| Andolino, 2011$^{26}$ | 60  | 40%    | 3.1                      | 30-48 Gy/3      | 60-125      | 50-104 | 80% IDL D95% PTV       | 82$^b$% | 90%      |
| Jung, 2013$^{27}$ | 92  | 26%    | 2.5                      | 45 Gy/3-4       | 96-113      | 80-94 | 85-90% IDL             | 87%      | 92% (3 years) |
| Sanuki, 2013$^{28}$ | 185 | 15%    | 2.7                      | 40 Gy/5         | 72          | 60    | 70-80% IDL             | 95%      | 93%      |
| Yoon, 2013$^{29}$ | 93  | 26%    | 2.0                      | 45 Gy/3-4       | 96-113      | 80-94 | D100% PTV              | 86%      | 95%$^b$ |
| Takeda, 2014$^{30}$ | 63  | 16%    | 2.6                      | 35-40 Gy/5      | 60-72       | 50-60 | 70-80% IDL             | 100%     | 95%      |
| Huertas, 2015$^{31}$ | 77  | 14%    | 2.4                      | 45 Gy/3         | 113         | 94    | 80% IDL                | 82%      | 99%      |
| Kimura, 2015$^{32}$ | 65  | 14%    | 1.6                      | 48 Gy/4         | 106         | 88    | Isocenter              | NR       | 100%     |
| Jang, 2013$^{32}$ | 108 | 10%    | 3.0                      | 51 Gy/3         | 138         | 115   | 70-80% IDL D97% PTV    | 83$^b$% | 100%     |

Abbreviations: BED, biologically equivalent dose; CP, Child-Pugh; EQD2, equivalent dose is 2 Gy fractions; fx, fractions; HCC, hepatocellular carcinoma; IDL, isodose line; LC, local control; n, patient number; NR, not reported; OS, overall survival; PTV, planning target volume.

*Studies included were published between 2002 and 2017 with more than 50 patients with HCC and reporting 2-year local control.

*Estimated from survival curve.
especially in CP-B/C patients. Therefore, these patients treated with a lower BED may not display a typical dose–response relationship seen in other tumors and patient groups due to the fragile nature of their underlying cirrhosis and competing risk factors for mortality, which could lead to erroneous dose–response relationship in some studies.36 Despite the knowledge that dose is correlated with LC, and LC is correlated with OS,22,37 only a minority of patients derive this survival benefit. This highlights the need for better patient selection methods, such as nomograms34,38 and/or biomarkers.39

Conclusion: Is there a dose response for HCC? Hepatocellular carcinoma is a relatively radiosensitive tumor in contrast to the relatively poor clinical prognosis of the patient group. In terms of LC and OS, the collective data suggest a threshold of 30 Gy EQD2 below which the impact of radiation is muted. Between approximately 53 and 84 Gy EQD2, the LC rates increase from 50% to 90%. Beyond 84 Gy, the degree of incremental LC improvement decreases while, depending on the anatomy, there is a continued incremental risk of toxicity. However, there is evidence that escalating the dose further may lead to a survival benefit in some patients based on correlation data from nonrandomized studies. Current dose recommendations such as 40 to 45 Gy in 3 fractions or 40 to 50 Gy in 5 fractions, which are within the 53 to 84 Gy EQD2 range, have been demonstrated to be safe and provide consistently high LC rates. Additional work is required to determine an optimal dose regimen for different subgroups.

Dosimetric Predictors of Hepatotoxicity: All for One and One for All?

Historically, conventional definitive fractionated radiation therapy to the liver resulted in a high incidence of “classical” RILD (cRILD), defined as hepatomegaly, anicteric ascites, and alkaline phosphatase elevated disproportionately compared to other hepatic enzymes.40 Despite the technological advancements in radiation therapy with SBRT and proton RT,39 3% to 44% of patients remain at risk of developing “nonclassical” RILD (ncRILD), which can be fatal in up to 5% to 13%,7,9,16,20,41-45 Various empiric end points have been used to describe ncRILD, including changes in CP score44,46,47 and Radiation Therapy Oncology Group (RTOG)/Common Terminology Criteria for Adverse Events (CTCAE) grade 2 to 4 laboratory abnormalities.9,43,48 The large variation in the reported rates of ncRILD suggests the need for a standardized consensus on reporting of ncRILD end points.44 One such end point may be CP score increase of 2 or greater (CP + 2). Chapman et al found this to be the strongest predictor of OS and RILD-specific survival on multivariate analysis (MVA).44 Treatment for RILD is essentially limited to supportive care, highlighting the importance of proper patient selection to prevent RILD. Further work is needed to develop more reliable and reproducible liver dosimetry constraints.49

At present, most of the data for dosimetric predictors of ncRILD are derived from patients with well-compensated liver function. In 2010, Quantitative Analysis of Normal Tissue Effects in the Clinic reported recommendations regarding the importance of mean normal liver dose of <18 Gy and <6 Gy for a 6-fraction SBRT regimen in patients with primary liver cancer with baseline CP-A and CP-B function, respectively.39,49 These early recommendations were largely based on a collection of studies using conventional or hyperfractionation studies for the treatment of primary liver cancer and/or metastatic disease to the liver50 as well as the early SBRT experience from Princess Margaret51,52 and University of Colorado.53 The University of Colorado phase 1 clinical trial of SBRT for liver metastases was the first to describe the importance of the liver volume spared, that is, the “critical volume model,” (eg, critical minimum volume of 700 cc of liver should be uninjured by SBRT by receiving <15 Gy) a concept akin to surgical sparing of the future liver remnant.53 This critical volume of liver spared concept has also been applied to patients with HCC.

Recent studies have reported significant heterogeneity in the types and cutoffs of dosimetric parameters correlated with RILD (Table 3). Several possible reasons why such heterogeneity exists include (1) limited sample size and RILD events in cohorts limiting statistical power, (2) variations in reporting of RILD outcomes, (3) the subjective nature of baseline liver assessments with traditional metrics (eg, CP-score),54 and (4) dosimetric models are based on anatomic computerized tomography (CT) imaging and do not incorporate regional functional heterogeneity within the liver. The last point is particularly relevant as many patients with HCC referred for SBRT have significant regional heterogeneity, partially due to prior LDT.55-57 Future studies would benefit from consensus reporting of toxicity outcomes and validation of objective parameters to evaluate liver function in the setting of RT. There is a need for validated global and spatial functional liver parameters that can be used for guiding precision RT treatment planning.

Velec et al performed a retrospective pooled analysis of 114 patients with HCC (CP-A 89%) treated on 2 prospective clinical trials with 6-fraction SBRT7,10 to identify risk factors associated with ncRILD as measured by CP + 2.20 Several factors, including dosimetric parameters of mean liver dose (odds ratio [OR]: 1.32, P = .004) and D800 cc (OR 1.12, P < .001), were significantly associated with CP + 2 on univariate analysis (UVA). The lowest CP + 2 risk was observed in CP-A5 patients who received mean liver doses and D800 cc < 15 Gy. Of note, on MVA only baseline CP-score (OR 4.85, P < .01) remained significant, highlighting the critical importance of baseline liver reserve. Dyk et al retrospectively analyzed 46 patients (CP-A 91%) treated with liver SBRT for either metastatic or primary liver malignancies and found the liver volume at 25 Gy (V25) > 32% was associated with CP-class progression on UVA.46 Son et al’s retrospective review of 47 patients with HCC (CP-A 68%) showed the volume of normal liver receiving <18 Gy should be >800 cc to avoid CP class progression on MVA.48 The results of a phase 2 study from Su et al identified dosimetric constraints predictive of incidence of CP + 1 or CP + 2 in 85 patients with HCC (CP-A 90.6%) treated to
Table 3. Summary of the Dosimetric Constraints of the Uninvolved Liver for Minimizing Risk of Radiation-Induced Liver Disease (RILD).

| Uninvolved Liver Constraints | Supporting Data | Baseline CP-A (%) | Dose/fx | Crude % RILD |
|-----------------------------|-----------------|-------------------|---------|--------------|
| Child-Pugh A                |                 |                   |         |              |
| Mean liver dose             |                 |                   |         |              |
| <20 Gy                      |                 | 88.5%             | Median 24-54 Gy/6 | 26% CP + 2  |
| Absolute/relative volume of liver spared | | | | |
| V25 Gy < 32%                | Dyk46           | 91%               | 36-60 Gy/3-6 | 22% CP + class |
| D800 cc < 15 Gy             | Velec20         | 88.5%             | Median 24-54 Gy/6 | 26% CP + 2  |
| D800 cc < 18 Gy             | Son48           | 88.9%             | Median 36 Gy/3 | 11% CP + class |
| V15 Gy ≤ 21.5%              | Su68            | 90.6%             | 30-50 Gy/3-5 | 23.5% CP + 1  |
| V<10 Gy ≥ 621.8 cc          | Su68            | 90.6%             | 30-50 Gy/3-5 | 23.5% CP + 1  |
| Child-Pugh B                |                 |                   |         |              |
| Mean liver dose             |                 |                   |         |              |
| ≤ 8.82 Gy                   | Lasley9         | 100%              | 40 Gy/5 | 38.8% G3-4 HE |
| Relative/absolute volume of liver irradiated | | | | |
| V<2.5 Gy = 810.8 cc         | Lasley9         | 100%              | 40 Gy/5 | 38.8% G3-4 HE |
| V<5 Gy = 1024.1 cc          |                 |                   |         |              |
| V<7.5 Gy = 1149.7 cc        |                 |                   |         |              |
| V<10 Gy = 1293.0 cc         |                 |                   |         |              |
| V<12.5 Gy = 1432.0 cc       |                 |                   |         |              |
| V<15 Gy = 1515.9 cc         |                 |                   |         |              |
| Absolute/relative volume of liver spared | | | | |
| D33% ≤ 7.37 Gy              | Lasley9         | 100%              | 40 Gy/5 | 38.8% G3-4 HE |

Abbreviations: CP, Child-Pugh; CP + 2, CP score increase of 2 or greater; CP + class, CP class progression; fx, fractionation; G3-4 HE, grade 3-4 hepatic enzyme elevation; V<X Gy, absolute normal liver volume (cc) spared from at least X Gy.

A total dose of 39 to 50 Gy in 3 to 5 fractions. This Chinese study demonstrated the significance of V15 ≤ 21.5%, absolute normal liver volume of 621.1 cc spared from at least 10 Gy (V < 10 Gy), and pretreatment CP score as predictors of RILD as measured by CP + 1 or CP + 2 on UVA, with external validation of a normal tissue complication probability model in Velec et al.’s cohort of CP-A patients (n = 101; AUC = 0.781). Together these results are broadly consistent highlighting the clinical relevance of V15 to V25 Gy and dose spared to a critical volume of 600 to 900 cc for a 5-fraction SBRT regimen as well as baseline CP score.

These studies were predominantly composed of well-compensated CP-A patients. Whether applying these dosimetric parameters to patients with more severe baseline liver disease (CP-B/C) results in the same risk of RILD is uncertain. Indiana University reported toxicity data from their phase I to II trial of SBRT for HCC in CP-A (n = 38) and -B (n = 21) patients. Due to increased toxicity observed in patients with CP > B7 in the phase I trial (3 events of classical RILD), the phase II study included only patients with CP ≤ B7 and tailored dosimetric constraints to baseline CP score. For a treatment regimen of 48 Gy in 3 fractions, CP-A patients were required to either limit the dose to 33% of the uninvolved liver (D33%) ≤ 10 Gy and/or maintain the liver volume receiving < 7 Gy to ≥500 cc. For a more conservative treatment regimen of 40 Gy in 5 fractions, CP-B7 patients had to meet constraints of D33% ≤ 18 Gy and/or ≥ 500 cc receiving < 12 Gy. Dosimetric correlates were identified for grade 3 to 4 hepatic enzyme toxicity observed in 10.5% and 38.8% of CP-A and CP-B patients, respectively. For CP-A patients, there was a trend toward importance of the dose to 500 cc (P = .054) as did volume of uninvolved liver (P = .082). However, in CP-B patients, significant predictors for RILD included mean dose ≥13.24 Gy (P = .026) and dose to D33% ≥ 12.50 Gy (P = .029); conversely, constraints without toxicity included mean dose ≤ 8.82 Gy (P = .026) and D33% ≤ 7.37 Gy (P = .029). Furthermore, the absolute volume of liver receiving doses as low as 2.5 to 15 Gy was significant with the highest statistical significance seen at the lowest doses. These collective findings are supportive of the liver being regarded as a parallel organ and suggest that even low dose received to the liver is important, especially in patients with less compensated liver function.

Caution when treating CP-B/C patients (CP-B7 69%) with SBRT was further supported by Princess Margaret’s prospective trial of 29 CP-B/C patients treated with a mean dose of 30 Gy in 6 fractions. Sixty-three percent of these patients experienced ncRILD as determined by CP + 2 within 3 months. For this study, the planning liver dosimetric parameters were based on the biological NTCP model with the goal of <5% and preferably less than 1% in fragile patients; however, there were no significant predictive dosimetric factors found on UVA.

Conclusion: Dosimetric predictors of hepatotoxicity—all for one and one for all? The limited data available regarding CP-B patients consistently suggest they are at heightened risk of RILD, and dosimetric parameters ought to be more conservative than for CP-A patients. The optimal liver dose constraints for CP-B+
patients, however, remain unclear at this time and highlight the need for additional research in this patient subgroup.

**Image Response Assessment**

The Liver Imaging Reporting and Data System (LI-RADS), initially launched in 2011 and recently updated in 2017, standardized the terminology and classification of liver lesions.\(^6\)\(^0\)\(^,\)\(^6\)\(^1\) The following characteristic imaging features of HCC are considered sensitive and specific enough to diagnose HCC independently (LI-RADS category 5) without requiring pathologic confirmation: mass-like, arterial-phase hyperenhancement, with either portal venous phase hypoenhancement and/or increase in size by ≥5 mm by 6 months, or definite tumor within the lumen of the hepatic veins.

The LI-RADS v2017 introduced 4 additional criteria specific for treatment response (LR-TR): (1) LR-TR nonevaluable due to poor image quality; (2) LR-TR viable for treated lesions with residual enhancing nodular, mass-like, or thick irregular tissue in or along the margin of the treated lesion with any of the following: arterial phase hyperenhancement, washout, or enhancement similar to pretreatment enhancement; (3) LR-TR nonviable for lesions without enhancement or a treatment-specific expected enhancement pattern; and (4) LR-TRequivocal for lesions with atypical enhancement pattern; and (4) LR-TR based on the modified Response Evaluation Criteria in Solid Tumors (mRECIST), and European Association for the Study of Liver Diseases (EASL) which define response assessment based on the volume of residual arterial hyperenhancement as a surrogate for tumor necrosis.\(^4\)\(^,\)\(^6\)\(^2\)\(^,\)\(^6\)\(^4\)

Historically, RECIST v1.1 criteria relied on changes in tumor size for posttreatment assessment which failed to detect nearly all complete responders (CRs) and underestimated the number of partial responders (PRs).\(^8\)\(^,\)\(^6\)\(^2\)\(^,\)\(^6\)\(^3\) Response Evaluation Criteria in Solid Tumors (mRECIST) and European Association for the Study of Liver Diseases (EASL) define response assessment based on the volume of residual arterial hyperenhancement as a surrogate for tumor necrosis.\(^4\)\(^,\)\(^6\)\(^2\)\(^,\)\(^6\)\(^4\) In mRECIST criteria, 100% disappearance of arterial phase hyperenhancement is considered a complete response (CR), while 30% decrease is considered a partial response (PR), and progressive disease is defined as 20% increase.\(^6\)\(^4\) If none of these changes are present, then the tumor is considered to be stable. The mRECIST, EASL, LR-TR criteria may be accurate for ablative, embolic, or systemic therapies, but application of these criteria to lesions treated with SBRT is unclear.\(^6\)\(^6\) Figure 1 demonstrates a characteristic CP-A5 patient with HCC treated with SBRT and the associated treatment response assessment over time.

Although the majority of HCC SBRT clinical trials continue to employ the mRECIST criteria for response assessment, there is an unmet need for a standardized response assessment system designed to address the unique imaging changes observed in HCC after SBRT.\(^2\)\(^8\)\(^\)\(^,\)\(^6\)\(^6\) Mendiratta-Lala et al recently highlighted this issue by performing a radiology–pathology correlation study.\(^6\)\(^7\) They evaluated 10 patients with HCC treated with SBRT who had pretreatment and serial multiphasic magnetic resonance imaging (MRI) or CT imaging for 12 months post-SBRT and either explant pathology or declining AFP values. Patients with pathologic explants with > 90% tumor necrosis or pretreatment AFP > 75 ng/mL that normalized to < 10 ng/mL within 1 year from SBRT without additional therapy were considered CRs. This study demonstrated that 40% of patients with CR had persistent tumor arterial hyperenhancement, 90% had persistent washout, but no patient had tumor size increases. Mannina et al retrospectively evaluated 38 patients with HCC (CP-A 45%) treated with SBRT prior to orthotropic liver transplantation (OLT) and demonstrated poor concordance of pathologic gold standard, defined as CR + PR, to radiologic scoring criteria of mRECIST (sensitivity 90%, specificity 17%), RECIST (sensitivity 54%, specificity 50%), and EASL (sensitivity 83%, specificity 18%); however, no patient was incorrectly categorized as having disease progression. An older report with an imaging–pathology correlation by Facciuto et al showed response assessment by RECIST v1.1 criteria significantly correlated with pathologic CR seen in 14% of patients and that radiologic response peaked at 3 months.\(^6\)\(^9\)

Other reports have described similar findings suggesting the importance of timing with regard to imaging response assessment using multiphase CT or MRI scans (Table 4). Sanuki et al demonstrated the median time to CR defined by arterial hyperenhancement was 5.9 months with a range of 1.2 to 34.2 months.\(^2\)\(^8\) Rates of CR increased from 24% at 3 months to 67% at 6 months and 71% at 12 months.\(^2\)\(^8\) Another Japanese cohort described by Kimura et al showed that 25.3% had residual arterial hyperenhancement at 3 months, which significantly declined to 2% at 6 months.\(^7\)\(^0\) No lesions increased in size.

Price et al demonstrated discordance between response evaluation by EASL and traditional RECIST assessment.\(^6\)\(^2\) Evaluating the mean tumor dimension decrease over time (RECIST), they found 35%, 37%, 48%, and 55% reduction by 3, 6, 9, and 12 months, respectively. However, ≥50% arterial hyperenhancement decline (partial response per EASL) was a more useful predictor in the first 6 to 12 months with patients demonstrating 59%, 69%, 81%, and 92% decreased hyperenhancement at 3, 6, 9, and 12 months, respectively. Oldrini et al focused specifically on imaging changes seen in multiphasic MRIs and demonstrated that mRECIST resulted in a higher rate of CRs compared to RECIST v1.1.\(^6\)\(^3\) Specifically, imaging CR response as defined by mRECIST versus RECIST was 57% versus 20% at 3 months, and 91.4% versus 41.6% at 12 months (P < .001). Perilesional arterial enhancement was present in 97% and 82% of patients at 3 and 12 months, respectively. The abovementioned studies are limited by the absence of pathologic confirmation of local tumor control respective to the corresponding imaging changes.

The imaging characteristics of HCC tumor response after SBRT is distinct compared to the changes seen in the surrounding uninvolved liver parenchyma. Regarding normal hepatic
Parenchyma changes, Park et al characterized the temporal change in arterial hyperenhancement corresponding to the high-dose area on multiphase CT scans during the post-SBRT follow-up period in 61 patients with HCC and found hyperenhancement increased from 12% at 1 month to 54% at 6 months. Delayed phase images showed isoattenuation or hyperattenuation in the majority of patients. Conversely, hypoattenuation ("washout") was rarely observed on the delayed phase, which may help distinguish tumor from post-treatment response. Moreover, the degree of underlying cirrhosis has been correlated with the amount of arterial hyperenhancement of liver parenchyma seen after SBRT for HCC. Kimura et al found the majority of CP-A patients (n = 64) converted from hypo- or isoattenuation in all enhanced phases to hyperattenuation within 6 months, whereas nearly all CP-B (n = 13) patients remained unchanged.

**Conclusion: Imaging response assessment.** Collectively, these studies highlight the potential pitfalls of radiographic response assessment after SBRT. Common observations across studies include (1) optimal time for response assessment is at least 6 to 12 months after SBRT; (2) stability or decrease in lesion size is associated with successful local control; (3) arterial phase hyperenhancement may persist despite pathologic CR; and (4) washout on delayed phases may persist after SBRT. If the RECIST, mRECIST, EASL, or LI-RADS TR v2017 criteria had been applied, many of these lesions would have been improperly categorized as treatment failures potentially leading to unnecessary additional therapies.

**Comparison With Other Local Treatments**

With so many LDT options, the question is often which LDT is optimal for patients ineligible for liver transplantation or surgical resection. Unfortunately, there currently is a paucity of head-to-head prospective randomized data, so answering this question often relies on synthesizing the results of various retrospective nonrandomized studies each with their particular weaknesses. Table 5 contains a brief summary of studies comparing SBRT alone or in combination with other modalities versus other LDT. The heterogeneity in patients, LDT techniques, and end points reported further challenges drawing definitive conclusions.

Surgical resection for medically operable patients with small early-stage HCC remains first-line treatment. There are no prospective data comparing the efficacy of resection to SBRT. Su et al performed a propensity-matched retrospective analysis of 117 patients (100% CP-A) with 1 to 2 small ≤5 cm HCC without prior LDTs. This Chinese study reported no differences in 5-year OS (74.3% vs 69.2%) and intrahepatic PFS (43.9% vs 35.9%) between those treated with SBRT versus...
## Table 4. Summary of Key Studies Evaluating Imaging Treatment Response After SBRT with Multiphasic CT and/or MRI.

| Study                  | n     | CP-A, % | Imaging Modality | Key Findings                                                                                                                                 |
|------------------------|-------|---------|------------------|----------------------------------------------------------------------------------------------------------------------------------------------|
| Mendiratta-Lala        | 10    | 80%     | CT or MRI        | In complete responders 12-months:  
* 40% with residual APHE  
* 90% with residual delayed wash-out  
* No size increase |
| Mannina                | 38    | 45%     | CT or MRI        | In Pathologic Responders (CR + PR; 68%)  
Radiographic response (CR + PR) prior to OLT  
* RECIST sensitivity 54%/specificity 50% ($\kappa = 0.09$)  
* mRECIST sensitivity 90%/specificity 18% ($\kappa = 0.09$)  
* EASL sensitivity 83%/specificity 18% ($\kappa = 0.09$)  
* No evidence of progressive disease  
* Mean 41% size reduction  
* Mean time to OLT: 8.8 months |
| Oldrini                | 35    | 85%     | MRI              | In observed patients  
3 months:  
* 54.3% decreased APHE  
* 97.1% with perilesional ring enhancement  
* 20% CR (RECIST) versus 57% CR (mRECIST)  
6 months:  
* 74.3% decreased APHE  
* No size increase  
12-months:  
* 41.6% CR (RECIST) versus 91.4% CR (mRECIST) |
| Sanuki                 | 38    | 90%     | CT               | In observed patients  
3 months:  
* 24% without APHE (designated CR by mRECIST)  
6 months:  
* 67% without APHE (designated CR by mRECIST)  
12 months:  
* 71% without APHE (designated CR by mRECIST)  
  Maximum overall CR rate: 93% (mRECIST)  
  Median time for complete APHE resolution: 5.9 months (1.2-34.2) |
| Kimura                 | 56    | 78%     | CT               | In observed patients  
3 months:  
* 25.3% residual APHE  
6 months:  
* 2% residual APHE (> 50% reduction of APHE suggestive of PR)  
* No size increase |
| Price                  | 26    | 54%     | CT or MRI        | 3 months:  
* 59% mean percentage necrosis (non-APHE)  
* 35% mean tumor dimension decrease  
6 months:  
* 69% mean percentage necrosis (non-APHE)  
* 37% mean tumor dimension decrease  
9 months:  
* 81% mean percentage necrosis (non-APHE)  
* 45% mean tumor dimension decrease  
12 months:  
* 92% mean percentage necrosis (non-APHE)  
  19% had > 50% decreased APHE = PR; 50% no APHE = CR  
  55% mean tumor dimension decrease |
| Facciuto               | 27    | NR      | CT or MRI        | Radiology–pathology correlation (RECIST v1.1/pathologic response)  
* Complete response: 30%/14%  
* Partial response: 7%/23%  
* Stable disease: 56%/no response 63%  
* Progressive disease 7%  
Peak time to response on imaging: 3 months |

Abbreviations: APHE, arterial phase hyperenhancement; CP, Child-Pugh; CR, complete response; n, patient number; CT, computerized tomography; EASL, European Association for the Study of Liver Diseases; MRI, magnetic resonance imaging; NR, not reported; OLT, orthotopic liver transplantation; PR, partial response; $\kappa$, weighted $\kappa$ statistic to analyze concordance; RECIST, Response Evaluation Criteria in Solid Tumors; mRECIST, modified Response Evaluation Criteria in Solid Tumors; SBRT, stereotactic body radiation therapy.

*Imaging–pathology correlation.
**Table 5. Summary of Key Clinical Data of SBRT Compared to Other Liver-Directed Therapies.**

| Study, Year | Study Type | n | Modalities Compared | Inclusion Criteria | SBRT Details | Tumor Control | OS | Comments |
|------------|------------|---|---------------------|-------------------|--------------|---------------|----|----------|
| Wahl, 2016 | Single-center retrospective | 224 | SBRT vs RFA | Inoperable, nonmetastatic | 30 Gy/3 or 50 Gy/5 | Freedom from local progression 1-year 97 vs 84% 2-year 84 vs 80% | 1-year 74 vs 70% 2-year 46 vs 53% | SBRT associated with better local control for tumors ≥ 2 cm |
| Rajyaguru, 2018 | NCDB | 3980 | SBRT vs RFA | T1-2N0M0 | ≤50 Gy/3-5 | NR | 5-year 19 vs 30%<sup>a</sup> | Significant patient differences remained after propensity matching SBRT patients were younger, but tended to have better performance status |
| Sapir, 2018 | Single-center retrospective | 209 | SBRT vs TACE | 1-2 tumors, non-metastatic | 30 Gy/3 or 50 Gy/5 | Absence of progressive disease by RECIST 1-year 97 vs 47%<sup>a</sup> 2-year 91 vs 23%<sup>a</sup> | No significant difference | |
| Su, 2016 | Single-center retrospective | 77 | TAE/TACE + SBRT vs SBRT | Tumor > 5 cm; CP-A/B; N0 M0; WHO PS 0-1 | 30-50 Gy/3-5 | Local relapse-free survival No significant difference | 1-year 76 vs 62%<sup>a</sup> 3-year 51 vs 33%<sup>a</sup> | BED<sub>10</sub> ≥ 100 Gy and EQD<sub>2</sub> ≥ 74 Gy significantly associated with improved OS, PFS, LRFS, and DMFS |
| Su, 2017 | Single-center retrospective | 117 | SBRT vs Resection | 1-2 tumors ≤ 5 cm; No prior LDT; CP-A; N0 M0; WHO PS 0-2; No PVT | 42-48 Gy/3-5 | Intrahepatic progression free survival | 1-year 100 vs 98% | SBRT recommended for patients with comorbidities who could not tolerate surgery or were medically inoperable. 1-year 84 vs 69% 3-year 92 vs 89% | No incidence of hepatic hemorrhage or pain in SBRT group, but more acute nausea and weight loss<sup>a</sup> |
| Yuan, 2013 | Single-center retrospective | 48 | SBRT vs resection | Stage I HCC; CP A-C; R0 surgical resection | 39-54 Gy/3-8 | Local control | 1-year 73 vs 89% 2-year 67 vs 73% | Higher proportion of CP-B/C in SBRT vs surgery, 55% vs 12%<sup>a</sup> Higher proportion of systemic disease in SBRT vs surgery, 41% vs 12%<sup>a</sup> |
| Jacob, 2015 | Single-center retrospective | 161 | TACE + SBRT vs TACE | Tumor ≥ 3 cm | 45 Gy / 3 | Crude local recurrence 11 vs 26%<sup>a</sup> | MST 33 vs 20 months<sup>a</sup> | SBRT started 2 wks post-TACE. Low rates of GI toxicity |
| Paik, 2016 | Single-center retrospective | 154 | iTACE + SBRT vs cTACE/iTACE + curative Tx vs iTACE + noncurative Tx | Initial TACE; 1 to 3 tumors ≤ 10 cm; CP-A/B; N0 M0 | 40-60 Gy/3-5 | iTACE + SBRT vs iTACE + noncurative Tx | 2-year 73 vs 54%<sup>a</sup> 5-year 53 vs 28%<sup>a</sup> | No significant differences in OS between iTACE + SBRT and cTACE/iTACE + curative Tx |

(continued)
| Study, Year | Study Type       | n   | Modalities Compared                  | Inclusion Criteria                                                                 | SBRT Details | Tumor Control                      | OS                  | Comments                                                                                                                                                   |
|------------|------------------|-----|--------------------------------------|--------------------------------------------------------------------------------|--------------|------------------------------------|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------|
| Sapisochin, 2017<sup>81</sup> | Single-center retrospective | 379 | SBRT vs TACE or RFA                  | Received bridging therapy of SBRT, TACE, or RFA prior to transplant             | 36 Gy/6      | Partial and complete necrosis in explanted livers No significant difference | No significant difference | No significant difference in risk of recurrence after liver transplant between SBRT, TACE, or RFA                                                                 |
| Shiozawa, 2015<sup>82</sup> | Single-center pilot | 73  | SBRT vs RFA                          | Solitary tumor ≤ 3 cm (RFA) or ≤ SBRT; CP-A/B8; Who PS 0-2; N0 M0               | 60 Gy/3-5 (adapted based on size) | Local control                  | 1-year 95 vs 100%                     | SBRT patients were deemed unable to receive RFA based on comorbidities, location, or size                                                                 |
| Yoon, 2018<sup>17</sup> | Single-center phase 3 | 90  | TACE-hypofractionated RT vs sorafenib | First line for CP-A patients with PVT                                         | 45 Gy in 2-3 Gy-fractions (3DCRT) | 1-yr 97 vs 97% PFS              | MST 55 vs 43 weeks<sup>a</sup> | In TACE-RT arm, no patient discontinued treatment due to hepatic decompensation. 11.1% in the TACE-RT arm were able to undergo curative surgical resection due to downstaging |

Abbreviations: BED, biological equivalent dose; CP, Child-Pugh; cTACE, complete TACE; curative, includes surgery, RFA, and percutaneous ethanol injection; DMFS, distant metastasis free survival; EQD2, equivalent dose in 2 Gy fractions; GI, gastrointestinal; HCC, hepatocellular carcinoma; iTACE, incomplete TACE; LDT, liver-directed therapy; LRFS, local recurrence free survival; MST, median survival time; n, patient number; NCDB, National Cancer Database; non-curative, includes TACE, sorafenib, or chemotherapy; NR, not reported; OS, overall survival; PFS, progression-free survival; PVT, portal vein thrombosis; RFA, radiofrequency ablation; SBRT, stereotactic body radiation therapy; TACE, transarterial chemoembolization; TAE, transarterial embolization; Tx, treatment; WHO, World Health Organization.

<sup>a</sup>Statistically significant.
resection; however, lack of reported local control is a limitation. Moreover, SBRT was administered to patients in this study when patients were deemed medically inoperable due to their comorbidities and/or tumor location. These results are consistent with retrospective data from Yuan et al showing no differences in 1- to 3-year LC and OS in patients with stage I HCC, despite statistically significant differences between the SBRT and surgical resection cohort with a higher proportion of CP-B/C patients (55% vs 12%) and systemic disease (41% vs 12%).

Although no randomized evidence exists comparing RFA to SBRT in the treatment of early-stage HCC, there are several nonrandomized comparative cohort studies. In Japan, a single-center pilot trial of SBRT versus RFA was performed in 73 patients with solitary HCC with CP-A to B8 cirrhosis (≤3 cm for RFA and ≤5 cm for SBRT) treated to 60 Gy in 3 to 5 fractions (dose reduction based on tumor size).82 Despite the SBRT cohort representing patients deemed unfit medically due to comorbidities, tumor location, and/or size >3 cm for RFA, there were no significant differences in 1-year local control (97% vs 97%) and OS (95% vs 100%) between SBRT and RFA, respectively. Wahl et al retrospectively compared 224 patients with inoperable nonmetastatic HCC treated with RFA or SBRT and used propensity scoring to adjust for imbalances in treatment assignment and found improved LC with SBRT.83 Increasing tumor size predicted worse LC with RFA, whereas LC was independent of size with SBRT. Tumors > 2 cm had a 3-fold increase in local progression rate with RFA versus SBRT. Overall survival and morbidity rates were not statistically different. Contrary to these findings, Rajyaguru et al’s propensity score-matched analysis of the National Cancer Database (NCDB) patients with HCC receiving RFA or SBRT as primary therapy showed superior 5-year OS with RFA (30% vs 19%).74 Although the number of patients analyzed was large (n = 3980), this study had several limitations including (1) no matching based on CP score or viral hepatitis status (not recorded in NCDB), (2) fibrosis score unknown in 72% of patients weakening the ability to control this confounder, (3) no distinction between single tumors with vascular invasion versus multifocal tumors < 5 cm, (4) significantly older patients treated with SBRT versus RFA (42% vs 26%, age ≥ 71 years), and (5) tumors treated with SBRT were larger (51% vs 34%, tumors > 3 cm). The limitations of these studies complicate unbiased comparison of SBRT and RFA for BCLC stage A HCC.

For BCLC class B and C patients without PVTT, TACE is considered by many to be the standard of care treatment. A propensity score analysis compared TACE versus SBRT in patients with 1 to 2 tumors found superior 2-year LC with SBRT (91% vs 23%).75 However, this large difference in LC did not translate into an OS benefit. Several studies have examined the potential role of combining SBRT with other LDTs. In a retrospective cohort study, Su et al examined TACE followed by SBRT versus SBRT alone for large (>5 cm) HCC and found superior survival in the combined group.76 Similarly, Jacob et al saw superior OS with TACE plus SBRT versus TACE alone for ≥3 cm tumors.79 In a study of incomplete TACE responders, Paik et al found no significant differences in 2- and 5-year OS between SBRT and curative treatment with surgery, RFA or PEI.80 Additionally, they found OS was superior with SBRT versus other noncurative treatment of additional TACE, sorafenib, or chemotherapy. Some of the best evidence to date is the recent publication of the START trial by Yoon et al as discussed earlier, demonstrating significantly improved PFS, OS, radiologic response rate, and median time to progression in CP-A patients with macrovascular invasion treated with TACE followed by hypofractionated RT over sorafenib alone.29 The combined findings of these articles support that select patients may benefit from combinations of LDTs with hypofractionated RT or SBRT and that these combinations appear to be well tolerated.

Transarterial chemoembolization, RFA, and SBRT have all been used as a bridge to transplantation. A retrospective cohort analysis testing TACE, RFA, and SBRT showed no survival difference between them in patients treated as bridge to transplantation at Princess Margaret.81 Of note, most patients treated by RFA (88%) met the Milan criteria for transplant, indicating they had limited stage disease. However, only 24% and 36% of TACE and SBRT patients met these criteria, respectively. A retrospective study by Mannina et al showed in 39 patients with HCC (CP-A 45%) treated with SBRT (dosing per institutional phase 1 and 2 trials) prior to OLT a pathological response rate (CR + PR) of 68% with no evidence of progression of the treated lesion at the time of OLT; albeit, there was viable tumor remaining in 74% of evaluable patients.58 Notably, 76% of these patients were initially ineligible for OLT listing due to medical comorbidities (63%) or substance abuse (13%).

Besides TACE, RFA, and SBRT, TARE is another LDT option for BCLC stage B/C tumors. Transarterial radioembolization involves administering yttrium-90 (Y-90)-containing microspheres through arterial catheters to the hepatic arteries feeding the tumor, enabling high radiation dose in the tumor and minimal exposure to normal tissues. Two large phase III trials tested selective internal radiation therapy versus sorafenib.83 Selective internal radiation therapy resulted in lower risk of progression in the liver and higher local response rates but no difference in OS.

Conclusion: Comparison with other local treatments. Most studies comparing 2 or 3 LDTs are retrospective and thus have low control of confounding variables. Even with matched analyses of large databases, the risk of imbalances between treatment groups is high. Despite many retrospective studies, the need for randomized trials to clarify the roles of SBRT, TACE, and RFA in HCC remains. A randomized phase III trial of sorafenib alone versus SBRT followed by sorafenib is currently ongoing (RTOG 1112, NCT01730937).

Comparison With PBT

The low radiation tolerance of cirrhotic liver tissue can limit the utilization of photon-based radiation therapy in treatment of
HCC. Due to the risk of RILD or deterioration in CP score, which in some cases may be fatal, only a small number of patients with relatively few small tumors may be eligible for SBRT. Data exploring the critical volume model discussed earlier in this review demonstrate reduced risk of toxicity by limiting low-dose radiation to uninvolved liver as much as possible. However, due to the intrinsic physical properties of photon or X-ray-based SBRT, there are limits to how much the low-dose volume can be reduced. Alternatively, the physical properties of PBT allows substantial decrease in low to moderate dose to surrounding tissue without compromising high-dose coverage of tumor and may make some patients with HCC ideal candidates for PBT.

Delivering protons to hepatic targets is technically challenging due to liver motion with breathing. The proton treatment technique of pencil beam scanning (PBS) allows better dose conformity to the target compared to the older more ubiquitous passive scattering proton therapy (PSPT) technique, but PBS is potentially more susceptible to interplay effects of liver movement. Successfully accounting and/or controlling motion is mandatory to use PBS for liver tumors. Breath-hold, gating, and repaint technologies may be solutions, but they are dependent on real-time monitoring of target motion with equipment that is fully integrated with the treatment machine (“real-time target monitoring”). However, real-time target monitoring is not available at most proton facilities, as image-guided RT is relatively immature in PBT compared to SBRT. Thus, most published work with PBT for HCC uses PSPT and only few proton centers treat liver tumors.

In silico comparative treatment plan studies demonstrated favorable dose distribution and sparing of liver tissue with protons versus photons. In a Danish study comparing proton and photon-based SBRT for liver tumors, protons halved the mean liver dose and spared 50% more normal liver volume at dose levels <15 Gy. A study by Kim et al showed similar dose reduction to the liver with a considerable reduction in liver volume receiving 5 to 45 Gy. A University of Pennsylvania study by Gandhi et al showed that both tumor location and size were correlated with the dosimetric superiority of PBT-SBRT over photon-based SBRT. Proton beam therapy generally provided dosimetric advantages in liver sparing for tumors >3 cm and located in the dome or central liver as well as for most tumors >5 cm.

In a phase I dose escalation study of unresectable HCC using moderately hypofractionated regimens of 60 to 72 Gy in 20 to 24 fractions, only 1 of the 27 patients had a 1-point increase in CP score, and no major hepatotoxicity was present. There were no statistical differences in LC or OS between the dose schedule arms. Loma Linda and Massachusetts General Hospital published their phase II results showing favorable LC, PFS, and OS rates with 63 Gy or 58 to 67.5 Gy, both in 15 fractions. Local control rates were as high as 95% at 2 years. Overall survival rates was also high; in a selected group of patients treated with PBT and subsequent liver transplant, 70% survived at 3 years. An interim analysis of a randomized trial testing PBT versus TACE in 69 patients with inoperable HCC from Loma Linda revealed excellent control rates of 88% and PFS and OS of 48 and 58%, respectively, among PBT-treated patients at 2 years. There was a nonsignificant trend for improved LC and PFS in patients treated with PBT.

A meta-analysis of 73 cohorts from 70 observational studies showed heavy-ion therapy and SBRT resulted in similar survival which was superior to that of conventional photon RT for HCC. Heavy-ion therapy resulted in the lowest risk of complications (6% vs 10% overall acute toxicity and 3% vs 6% late toxicity, heavy ion therapy vs SBRT, respectively). However, these results are based on a comparison of very heterogeneous patient populations and treatment techniques, including substantially different total dose (median dose: 69.3 GyE charged particle therapy vs 37 Gy SBRT vs 50.9 Gy conventional photon RT).

**Conclusion: Comparison with PBT.** Where photon therapy of HCC is clearly limited in terms of volume and target numbers, PBT may allow for treatment of more advanced cases of HCC. Kim et al assessed 41 patients with HCC having PVTT treated with PBT using a technique that delivered increased dose to the tumor thrombus relative to the primary tumor while treating both the primary and the thrombus simultaneously in the same RT field (simultaneous integrated boost). Sixty-one percent of the tumors were >5 cm. Of patients responding to treatment, 66% were alive at 2 years. The first randomized phase III trial of protons versus photon therapy for HCC is currently enrolling (NRG-GI003, NCT03186898).

**Summary**

Hepatocellular carcinoma is a common cause of cancer-related death worldwide. Treating HCC is challenging and complex because of the natural history of the disease itself and the prevalence of advanced comorbidities seen in patients with HCC. Patients who are ineligible for liver transplant or partial hepatectomy have many different LDT options. Choosing an option that maximizes clinical benefits and limits risk of toxicity is essential. Stereotactic body radiation therapy has emerged as an effective LDT for properly selected patients with HCC having excellent rates of LC and minimal treatment associated morbidity, especially in those with well-compensated liver function (eg, CP-A). Technological advancements in SBRT and PBT have facilitated dose escalation, despite the inherent radiosensitivity of normal hepatic parenchyma. However, whether further dose escalation is beneficial (eg, beyond 84 Gy EQD2) remains controversial. Further study is necessary to fully characterize and understand the HCC dose–response curve. One key limitation for dose escalation is the need for validated dosimetric parameters predictive of RILD. To achieve this, objective global and spatial metrics of baseline liver function that have been validated in SBRT-treated patients are warranted, in addition to a standardized consensus regarding reporting hepatotoxicity endpoints. Current available data suggest patients with CP-B7+ cirrhosis ought to have more conservative dosimetric constraints because they are at
elevated risk of RILD. A need remains for validated consensus criteria to improve accuracy of post-SBRT imaging-based response assessment to minimize the risk of over-treatment. Lastly, despite the challenges with comparing SBRT to other treatment modalities in the absence of randomized data, SBRT appears to be an effective LDT for local control with a safe toxicity profile in well-selected patients, and further work is ongoing regarding the role of SBRT in the setting of combined modality treatments. Ongoing phase III clinical trials will address the questions of SBRT versus PBT (NRG-G1003, NCT03186898) and sorafenib with/or without SBRT (RTOG 1112, NCT01730937).

Declaration of Conflicting Interests

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Michael I. Lock has received fees as a consultant or research funding from Accuray Incorporated, 3 M Canada, and Abbvie Corporation.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7-30.
2. Global Burden of Disease Liver Cancer Collaboration. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the Global Burden of Disease Study 2015. JAMA Oncol. 2017;3(12):1683-1691.
3. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology. 1999;30(6):1434-1440.
4. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35(3):421-430.
5. Russell AH, Clyde C, Wasserman TH, Turner SS, Rotman M. Accelerated hyperfractionated hepatic irradiation in the management of patients with liver metastases: results of the RTOG dose escalating protocol. Int J Radiat Oncol Biol Phys. 1993;27(1):117-123.
6. Benson AB, 3rd, D’Angela MI, Abbott DE, et al. NCCN guidelines insights: hepatobiliary cancers, version 1.2017. J Natl Compr Canc Netw. 2017;15(5):563-573.
7. Bukold A, Massey CA, Kim JJ, et al. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol. 2013;31(13):1631-1639.
8. Cardenes HR, Price TR, Perkins SM, et al. Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma. Clin Transl Oncol. 2010;12(3):218-225.
9. Lasley FD, Mannina EM, Johnson CS, et al. Treatment variables related to liver toxicity in patients with hepatocellular carcinoma, Child-Pugh class A and B enrolled in a phase 1-2 trial of stereotactic body radiation therapy. Pract Radiat Oncol. 2015;5(5):e443-e449.
10. Culleton S, Jiang H, Haddad CR, et al. Outcomes following definitive stereotactic body radiotherapy for patients with Child-Pugh B or C hepatocellular carcinoma. Radiother Oncol. 2014;111(3):412-417.
11. Kang JK, Kim MS, Cho CK, et al. Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization. Cancer. 2012;118(21):5424-5431.
12. Mendez Romero A, Wunderink W, Hussain SM, et al. Stereotactic body radiation therapy for primary and metastatic liver tumors: A single institution phase I-II study. Acta Oncol. 2006;45(7):831-837.
13. Scorsetti M, Comito T, Cozzi L, et al. The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on stereotactic body radiation therapy (SBRT). J Cancer Res Clin Oncol. 2015;141(7):1301-1309.
14. Xi M, Zhang L, Zhao L, et al. Effectiveness of stereotactic body radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombosis. PLos One. 2013;8(5):e63864.
15. Kang J, Nie Q, Du R, et al. Stereotactic body radiotherapy combined with transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombosis. Mol Clin Oncol. 2014;2(1):43-50.
16. Li XL, Guo WX, Hong XD, et al. Efficacy of the treatment of transarterial chemoembolization combined with radiotherapy for hepatocellular carcinoma with portal vein tumor thrombus: a propensity score analysis. Hepatol Res. 2016;46(11):1088-1098.
17. Yoon SM, Ryoo BY, Lee SJ, et al. Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion: a randomized clinical trial. JAMA Oncol. 2018;4(5):661-669.
18. Kwon JH, Bae SH, Kim JY, et al. Long-term effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablation therapy or surgical resection. Stereotactic radiotherapy for liver cancer. BMC Cancer. 2010;10:475.
19. Su TS, Liang P, Lu HZ, et al. Stereotactic body radiation therapy for small primary or recurrent hepatocellular carcinoma in 132 Chinese patients. J Surg Oncol. 2016;113(2):181-187.
20. Velec M, Haddad CR, Craig T, et al. Predictors of liver toxicity following stereotactic body radiation therapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2017;97(5):939-946.
21. Lauw A, Sinclair K, Lock M, et al. Determination and comparison of radiotherapy dose responses for hepatocellular carcinoma and metastatic colorectal liver tumours. Br J Radiol. 2013;86(1027):20130147.
22. Jang WI, Kim MS, Bae SH, et al. High-dose stereotactic body radiotherapy correlates increased local control and overall survival in patients with inoperable hepatocellular carcinoma. Radiother Oncol. 2013;8:250.
23. Ohri N, Tome WA, Mendez Romero A, et al. Local control after stereotactic body radiation therapy for liver tumors [published
online January 6, 2018]. Int J Radiat Oncol Biol Phys. 2018. pii: S0360-3016(17)34525-X. doi: 10.1016/j.ijrobp.2017.12.288

24. Yamashita H, Onishi H, Murakami N, et al. Survival outcomes after stereotactic body radiotherapy for 79 Japanese patients with hepatocellular carcinoma. J Radiat Res. 2015;56(3):561-567.

25. Bibault JE, Dewas S, Vautravers-Dewas C, et al. Stereotactic body radiation therapy for hepatocellular carcinoma: prognostic factors of local control, overall survival, and toxicity. PLoS One. 2013;8(10):e77472.

26. Andolino DL, Johnson CS, Maluccio M, et al. Stereotactic body radiotherapy for primary hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2011;81(4):e447-453.

27. Jung J, Yoon SM, Kim SY, et al. Radiation-induced liver disease after stereotactic body radiotherapy for small hepatocellular carcinoma: clinical and dose-volumetric parameters. Radiat Oncol. 2013;8:249.

28. Sanuki N, Takeda A, Mizuno T, et al. Tumor response on CT following hypofractionated stereotactic ablative body radiotherapy for small hypervascular hepatocellular carcinoma with cirrhosis. AJR Am J Roentgenol. 2013;201(6):W812-W820.

29. Yoon SM, Lim YS, Park MJ, et al. Stereotactic body radiation therapy as an alternative treatment for small hepatocellular carcinoma. PLoS One. 2013;8(11):e79854.

30. Takeda A, Sanuki N, Eriyuchi T, et al. Stereotactic ablative body radiotherapy for previously untreated solitary hepatocellular carcinoma. J Gastroenterol Hepatol. 2014;29(2):372-379.

31. Huertas A, Baumann AS, Saunier-Kubs F, et al. Stereotactic body radiation therapy as an ablative treatment for inoperable hepatocellular carcinoma. Radiother Oncol. 2015;115(2):211-216.

32. Kimura T, Aikata H, Takahashi S, et al. Stereotactic body radiotherapy for patients with small hepatocellular carcinoma ineligible for resection or ablation therapies. Hepatol Res. 2015;45(4):378-386.

33. Seong J, Lee IJ, Shim SJ, et al. A multicenter retrospective cohort study of practice patterns and clinical outcome on radiotherapy for hepatocellular carcinoma in Korea. Liver Int. 2009;29(2):147-152.

34. Vickress J, Lock M, Lo S, et al. A multivariable model to predict survival for patients with hepatic carcinoma or liver metastasis receiving radiotherapy. Future Oncol. 2017;13(1):19-30.

35. Klein J, Korol R, Lo SS, et al. Stereotactic body radiotherapy: an effective local treatment modality for hepatocellular carcinoma. Future Oncol. 2014;10(14):2227-2241.

36. McCamron R, Scheffer TE, Gaspar LE, Zaemisch R, Gravdahl D, Kavanagh B. Observation of a dose-control relationship for lung and liver tumors after stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2009;73(1):112-118.

37. Tanguturi SK, Wo JY, Zhu AX, Dawson LA, Hong TS. Radiation therapy for liver tumors: ready for inclusion in guidelines? Oncologist. 2014;19(8):868-879.

38. Toesca DAS, Osmundson EC, von Eyben R, Shaffer JL, Koong AC, Chang DT. Assessment of hepatic function decline after stereotactic body radiation therapy for primary liver cancer. Pract Radiat Oncol. 2017;7(3):173-182.

39. Munoz-Schuffenecker P, Ng S, Dawson LA. Radiation-induced liver toxicity. Semin Radiat Oncol. 2017;27(4):350-357.

40. Ingold JA, Reed GB, Kaplan HS, Bagshaw MA. Radiation hepatitis. Am J Roentgenol Radium Ther Nucl Med. 1965;93:200-208.

41. Que J, Kuo HT, Lin LC, et al. Clinical outcomes and prognostic factors of cyberknife stereotactic body radiation therapy for unresectable hepatocellular carcinoma. BMC Cancer. 2016;16:451.

42. Sanuki N, Takeda A, Oku Y, et al. Stereotactic body radiotherapy for small hepatocellular carcinoma: a retrospective outcome analysis in 185 patients. Acta Oncol. 2014;53(3):399-404.

43. Sanuki N, Takeda A, Oku Y, et al. Influence of liver toxicities on prognosis after stereotactic body radiation therapy for hepatocellular carcinoma. Hepatol Res. 2015;45(5):540-547.

44. Chapman TR, Bowen SR, Schaub SK, et al. Toward consensus reporting of radiation-induced liver toxicity in the treatment of primary liver malignancies: defining clinically relevant endpoints. Pract Radiat Oncol. 2018;8(3):157-166. doi: 10.1016/j.prro.2017.10.013

45. Song JH, Jeong BK, Choi HS, et al. Defining radiation-induced hepatic toxicity in hepatocellular carcinoma patients treated with stereotactic body radiotherapy. J Cancer. 2017;8(19):4155-4161.

46. Dyk P, Weiner A, Badiyan S, Myerson R, Parikh P, Olsen J. Effect of high-dose stereotactic body radiation therapy on liver function in the treatment of primary and metastatic liver malignancies using the Child-Pugh score classification system. Pract Radiat Oncol. 2015;5(3):176-182.

47. Son SH, Kay CS, Song JH, et al. Dosimetric parameter predicting the deterioration of hepatic function after helical tomotherapy in patients with unresectable locally advanced hepatocellular carcinoma. Radiat Oncol. 2013;8:11.

48. Son SH, Choi BO, Ryu MR, et al. Stereotactic body radiotherapy for patients with unresectable primary hepatocellular carcinoma: dose-volumetric parameters predicting the hepatic complication. Int J Radiat Oncol Biol Phys. 2010;78(4):1073-1080.

49. Pan CC, Kavanagh BD, Dawson LA, et al. Radiation-associated liver injury. Int J Radiat Oncol Biol Phys. 2010;76(suppl 3):S94-S100.

50. Jackson A, Ten Haken RK, Robertson JM, Kessler ML, Kutchler GJ, Lawrence TS. Analysis of clinical complication data for radiation hepatitis using a parallel architecture model. Int J Radiat Oncol Biol Phys. 1995;31(4):883-891.

51. Dawson LA, Normolle D, Balter JM, McGinn CJ, Lawrence TS, Ten Haken RK. Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys. 2002;53(4):810-821.

52. Tse RV, Hawkins M, Lockwood G, et al. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol. 2008;26(4):657-664.

53. Scheffer TE, Kavanagh BD, Timmerman RD, Cardenes HR, Baron A, Gaspar LE. A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases. Int J Radiat Oncol Biol Phys. 2005;62(5):1371-1378.

54. Child CG, Turtoge JG. Surgery and portal hypertension. Major Probl Clin Surg. 1964;1:1-85.

55. Bowen SR, Chapman TR, Borgman J, et al. Measuring total liver function on sulfur colloid SPECT/CT for improved risk
stratification and outcome prediction of hepatocellular carcinoma patients. *EJM/MI* Res. 2016;6(1):57.

56. Bowen SR, Saini J, Chapman TR, et al. Differential hepatic avoidance radiation therapy: proof of concept in hepatocellular carcinoma patients. *Radiother Oncol*. 2015;115(2):203-210.

57. Matesan MM, Bowen SR, Chapman TR, et al. Assessment of functional liver reserve: old and new in 99mTc-sulfur colloid scintigraphy. *Nucl Med Commun*. 2017;38(7):577-586.

58. Su TS, Luo R, Liang P, Cheng T, Zhou Y, Huang Y. A prospective cohort study of hepatic toxicity after stereotactic body radiation therapy for hepatocellular carcinoma [published online January 6, 2018]. *Radiother Oncol*. 2018. pii: S0360-3016(17)34525-X. doi: 10.1016/j.ijrobp.2017.12.288

59. Dawson LA, Eccles C, Craig T. Individualized image guided iso-NTCP based liver cancer SBRT. *Acta Oncol*. 2006;45(7): 856-864.

60. Mitchell DG, Bruix J, Sherman M, Sirlin CB. LI-RADS (Liver Imaging Reporting and Data System): summary, discussion, and consensus of the LI-RADS Management Working Group and future directions. *Hepatology*. 2015;61(3):1056-1065.

61. Elsayes KM, Hooker JC, Agrons MM, et al. 2017 Version of LI-RADS for CT and MR imaging: an update. *Radiographics*. 2017; 37(7):1994-2017.

62. Price TR, Perkins SM, Sandrasegaran K, et al. Evaluation of response after stereotactic body radiotherapy for hepatocellular carcinoma. *Cancer*. 2012;118(12):3191-3198.

63. Oldrini G, Huertas A, Renard-Oldrini S, et al. Tumor response assessment by MRI following stereotactic body radiation therapy for hepatocellular carcinoma. *PLoS One*. 2017;12(4):e0176118.

64. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. *Sem Liver Dis*. 2010;30(1): 52-60.

65. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. *J Natl Cancer Inst*. 2000;92(3):205-216.

66. Vincenzi B, Di Maio M, Silletta M, et al. Prognostic relevance of objective response according to easl criteria and mrecist criteria in hepatocellular carcinoma patients treated with loco-regional therapies: a literature-based meta-analysis. *PLos One*. 2015; 10(7): e0133488.

67. Mendiratta-Lala M, Gu E, Owen D, et al. Imaging findings within the first 12 months of hepatocellular carcinoma treated with stereotactic body radiation therapy [published online January 6, 2018]. *Int J Radiat Oncol Biol Phys*. 2017. pii: S0360-3016(17)34525-X. doi: 10.1016/j.ijrobp.2017.12.288

68. Mannina EM, Cardenes HR, Lasley FD, et al. Role of stereotactic body radiation therapy before orthotopic liver transplantation: retrospective evaluation of pathologic response and outcomes. *Int J Radiat Oncol Biol Phys*. 2017;97(5):931-938.

69. Facciuto ME, Singh MK, Rochon C, et al. Stereotactic body radiation therapy in hepatocellular carcinoma and cirrhosis: evaluation of radiological and pathological response. *J Surg Oncol*. 2012;105(7):692-698.

70. Kimura T, Takahashi S, Kenjo M, et al. Dynamic computed tomography appearance of tumor response after stereotactic body radiation therapy for hepatocellular carcinoma: how should we evaluate treatment effects? *Hepatol Res*. 2013;43(7):717-727.

71. Park MJ, Kim SY, Yoon SM, et al. Stereotactic body radiotherapy-induced arterial hypervascularity of non-tumorous hepatic parenchyma in patients with hepatocellular carcinoma: potential pitfalls in tumor response evaluation on multiphase computed tomography. *PLoS One*. 2014;9(2):e90327.

72. Kimura T, Takahashi S, Takahashi I, et al. The time course of dynamic computed tomographic appearance of radiation injury to the cirrhotic liver following stereotactic body radiation therapy for hepatocellular carcinoma. *PLos One*. 2015;10(6):e0125231.

73. Wahl DR, Stenmark MH, Tao Y, et al. Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma. *J Clin Oncol*. 2016;34(5):452-459.

74. Rajaguru DJ, Borgert AJ, Smith AL, et al. Radiofrequency ablation versus stereotactic body radiotherapy for localized hepatocellular carcinoma in nonsurgically managed patients: analysis of the national cancer database. *J Clin Oncol*. 2018;36(6):600-608.

75. Sapir E, Tao Y, Schipper MJ, et al. Stereotactic body radiation therapy as an alternative to transarterial chemoembolization for hepatocellular carcinoma. *Int J Radiat Oncol Biol Phys*. 2018;100(1):122-130.

76. Su TS, Lu HZ, Cheng T, et al. Long-term survival analysis in combined transarterial embolization and stereotactic body radiotherapy therapy versus stereotactic body radiotherapy monotherapy for unresectable hepatocellular carcinoma >5 cm. *BMC Cancer*. 2016;16(1):834.

77. Su TS, Liang P, Liang J, et al. Long-term survival analysis of stereotactic ablative radiotherapy versus liver resection for small hepatocellular carcinoma. *Int J Radiat Oncol Biol Phys*. 2017; 98(3):639-646.

78. Yuan Z, Tian L, Wang P, Song Y, Dong Y, Zhuang H. Comparative research on the efficacy of CyberKnife(R) and surgical excision for stage I hepatocellular carcinoma. *Onco Targets Ther*. 2013;6:1527-1532.

79. Jacob R, Turley F, Redden DT, et al. Adjuvant stereotactic body radiotherapy following transarterial chemoembolization in patients with non-resectable hepatocellular carcinoma tumours of ≥ 3 cm. *HPB (Oxford)*. 2015;17(2):140-149.

80. Paik EK, Kim MS, Jang WI, et al. Benefits of stereotactic ablative radiotherapy combined with incomplete transcatheter arterial chemoembolization in hepatocellular carcinoma. *Radiat Oncol*. 2016;11:22.

81. Sapiscochin G, Barry A, Doherty M, et al. Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis. *J Hepatol*. 2017;67(1):92-99.

82. Shiozawa K, Watanabe M, Ikehara T, et al. Comparison of percutaneous radiofrequency ablation and CyberKnife(R) for initial solitary hepatocellular carcinoma: a pilot study. *World J Gastroenterol*. 2015;21(48):13490-13499.

83. Vilgrain V, Pereira H, Assenat E, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable
hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. *Lancet Oncol*. 2017;18(12):1624-1636.

84. Petersen JB, Lassen Y, Hansen AT, Muren LP, Grau C, Hoyer M. Normal liver tissue sparing by intensity-modulated proton stereotactic body radiotherapy for solitary liver tumours. *Acta Oncol*. 2011;50(6):823-828.

85. Kim JY, Lim YK, Kim TH, et al. Normal liver sparing by proton beam therapy for hepatocellular carcinoma: comparison with helical intensity modulated radiotherapy and volumetric modulated arc therapy. *Acta Oncol*. 2015;54(10):1827-1832.

86. Gandhi SJ, Liang X, Ding X, et al. Clinical decision tool for optimal delivery of liver stereotactic body radiation therapy: photons versus protons. *Pract Radiat Oncol*. 2015;5(4):209-218.

87. Kim TH, Park JW, Kim YJ, et al. Phase I dose-escalation study of proton beam therapy for inoperable hepatocellular carcinoma. *Cancer Res Treat*. 2015;47(1):34-45.

88. Hong TS, Wo JY, Yeap BY, et al. Multi-institutional phase II study of high-dose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma. *J Clin Oncol*. 2016;34(5):460-468.

89. Bush DA, Kayali Z, Grove R, Slater JD. The safety and efficacy of high-dose proton beam radiotherapy for hepatocellular carcinoma: a phase 2 prospective trial. *Cancer*. 2011;117(13):3053-3059.

90. Bush DA, Smith JC, Slater JD, et al. Randomized clinical trial comparing proton beam radiation therapy with transarterial chemoembolization for hepatocellular carcinoma: results of an interim analysis. *Int J Radiat Oncol Biol Phys*. 2016;95(1):477-482.

91. Qi WX, Fu S, Zhang Q, Guo XM. Charged particle therapy versus photon therapy for patients with hepatocellular carcinoma: a systematic review and meta-analysis. *Radiother Oncol*. 2015;114(3):289-295.

92. Kim DY, Park JW, Kim TH, et al. Risk-adapted simultaneous integrated boost-proton beam therapy (SIB-PBT) for advanced hepatocellular carcinoma with tumour vascular thrombosis. *Radiother Oncol*. 2017;122(1):122-129.